Gary Falcetano, PA-C, AE-C, explains that proactively managing seasonal allergies can significantly decrease the overall inflammatory burden, thereby improving both physical symptoms and potentially mitigating neuroinflammation's impact on mental well-being.
Gary Falcetano, PA-C, AE-C, explains that proactively managing seasonal allergies can significantly decrease the overall inflammatory burden, thereby improving both physical symptoms and potentially mitigating neuroinflammation's impact on mental well-being.
Gary Falcetano, PA-C, AE-C, US scientific affairs manager for allergy at Thermo Fisher Scientific, emphasizes in this interview with in an interview with The American Journal of Managed Care® (AJMC®) that inflammation is central to the burden of seasonal allergies on both mental and physical health. He explains that allergies are a cumulative threshold disease, meaning most patients are reactive to multiple triggers, often a mix of year-round allergens like dust mites, molds, and pet dander, compounded by seasonal pollens.
This additive exposure can push individuals beyond their allergic threshold, leading to severe and difficult-to-control symptoms, even with medication. Falcetano recommends that once patients confirm their allergies and identify specific triggers, they should implement preventative measures to reduce their overall allergen load. By controlling overt allergic symptoms, the overall inflammatory load is reduced, which could, in turn, decrease neuroinflammation and positively impact brain regions involved in mood regulation.
This transcript was lightly edited for clarity.
Transcript
AJMC: What steps can patients with seasonal allergies take to proactively protect their mental and physical health during peak allergy season, especially considering the inflammatory burden and its impact on the brain?
Falcetano: Inflammation really is at the heart of everything we're talking about. Once patients have confirmed that they're allergic and they've identified their triggers, then they can institute preventative measures to reduce their overall allergen load. Allergy is a cumulative threshold disease and most patients with respiratory allergies have more than 1 trigger. Someone who's allergic to one thing is usually allergic to something else.
Exposure to each of these triggers can really add to that cumulative allergic load and inflammatory load, and cause patients to exceed their individual allergic thresholds when experiencing symptoms. Often patients are allergic to year-round allergic triggers like dust mites, molds, or pets, and then when spring pollen season arrives, they begin experiencing increased and difficult-to-control symptoms—and it's all additive. It pushes them over that threshold. It makes the symptoms very difficult to control, even if they are allergic. Antihistamines may not cut it, even inhaled nasal steroids may not cut it.
By incorporating exposure-reduction strategies like using dust mite impermeable bedding covers, keeping windows closed, and keeping pets out of the bedroom, patients can be proactive in managing what is driving their symptoms. Looking at that total burden and then being proactive in reducing exposure at least somewhat, again, to all the things that you're sensitized to can improve their symptomatology and make medications more efficacious.
When obvious allergic symptoms are controlled, the runny nose, cough, postnasal drip, we would hope that the overall inflammatory load will decrease. Decreasing cytokines and other inflammatory mediators from entering the brain could potentially improve neuroinflammation and the downstream effects on the brain regions that are involved in mood regulation.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Chronic Spontaneous Urticaria Linked to Higher Patient Burden, Worse Quality of Life
August 7th 2025Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse quality of life and higher health care costs, underscoring the critical need for better treatments.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Earlier Food Introduction Dramatically Reduces Peanut, Egg, Milk Allergy Rates in Infants
July 30th 2025When updated food allergy prevention guidelines were directly provided to families, they led to earlier allergen introduction in infants and significantly reduced the prevalence of IgE-mediated peanut, egg, and cow's milk allergies.
Read More